NFL Biosciences SAS (ALNFL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NFL Biosciences SAS (ALNFL) has a cash flow conversion efficiency ratio of 0.030x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€57.51K ≈ $67.24K USD) by net assets (€1.91 Million ≈ $2.23 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NFL Biosciences SAS (ALNFL) net asset quality to measure how much of total assets are equity-financed.
NFL Biosciences SAS - Cash Flow Conversion Efficiency Trend (2020–2022)
This chart illustrates how NFL Biosciences SAS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check NFL Biosciences SAS (ALNFL) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
NFL Biosciences SAS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NFL Biosciences SAS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
OpTeam S.A.
WAR:OPM
|
-0.102x |
|
Altamin Ltd
AU:AZI
|
-0.491x |
|
Mahube Infrastructure Ltd
JSE:MHB
|
0.009x |
|
Vogiatzoglou Systems S.A
AT:VOSYS
|
0.047x |
|
SANCUS LENDING GROUP LTD.
F:97F
|
N/A |
|
Vishwaraj Sugar Industries Limited
NSE:VISHWARAJ
|
-0.120x |
|
Tasman Resources Ltd
AU:TAS
|
-0.077x |
|
Emova Group SA
PA:ALEMV
|
0.190x |
Annual Cash Flow Conversion Efficiency for NFL Biosciences SAS (2020–2022)
The table below shows the annual cash flow conversion efficiency of NFL Biosciences SAS from 2020 to 2022. For the full company profile with market capitalisation and key ratios, see how much is NFL Biosciences SAS worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | €844.00K ≈ $986.72K |
€104.89K ≈ $122.63K |
0.124x | +369.60% |
| 2021-12-31 | €3.29 Million ≈ $3.84 Million |
€87.00K ≈ $101.71K |
0.026x | -95.27% |
| 2020-12-31 | €150.03K ≈ $175.39K |
€83.91K ≈ $98.10K |
0.559x | -- |
About NFL Biosciences SAS
NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company's pipeline includes NFL-101, a drug candidate for smoking cessation, currently under Phase 2b clinical trials; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding… Read more